BDSX
BIODESIX INC
Key Financials
EPS (Diluted)
$-4.67
↓ 1315.2%
Net Income
$-35265000
↑ 17.9%
Revenue
$88.5M
↑ 24.1%
Operating Income
$-27873000
↑ 19.2%
Total Liabilities
$89.9M
↑ 17.8%
Shareholders' Equity
$-2465000.00
↓ 111.8%
Long-term Debt
$50.0M
↑ 24.9%
Total Assets
$87.5M
↓ 10.0%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 4 | 10/2/2026 | View on SEC |
| 4 | 8/13/2026 | View on SEC |
| 4 | 8/12/2026 | View on SEC |
| 10-Q | 8/5/2026 | View on SEC |
| 8-K | 8/5/2026 | View on SEC |
| 4 | 7/2/2026 | View on SEC |
| SCHEDULE 13G | 6/18/2026 | View on SEC |
| 424B3 | 6/1/2026 | View on SEC |
| EFFECT | 5/29/2026 | View on SEC |
| CORRESP | 5/27/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | BDSX |
| Company Name | BIODESIX INC |
| CIK | 1439725 |
| Sector | Services-Medical Laboratories |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 8071 |
| SIC Description | Services-Medical Laboratories |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 303-417-0500 |